

**Amendments to the Claims:**

This listing of claims will replace all prior versions, and listings, of claims in the application:

**Listing of Claims:**

1. (Canceled)
2. (Currently Amended) A method for preventing of a motoneuron disease in a patient ~~in need thereof~~ by increasing the survival and/or growth of motoneurons in said patient comprising administering to the said patient a pharmaceutically effective amount of a low molecular weight heparin.
3. (Original) The method according to claim 2 wherein the motoneuron disease is amyotrophic lateral sclerosis, progressive spinal muscular atrophy, infantile muscular atrophy or lateral sclerosis.
4. (Currently Amended) The method according to one of claims ~~1 to 2~~ or 3, wherein the low molecular weight heparin has a mean molecular weight of between 1000 and 10000 daltons.
5. (Original) The method according to claim 4, wherein the low molecular weight heparin has a mean molecular weight of between 1500 and 6000 daltons.
6. (Original) The method according to claim 4, wherein the low molecular weight heparin has a mean molecular weight of between 4000 and 5000 daltons.
7. (Currently Amended) The method according to one of claims ~~1 to 2~~ or 3, wherein the low molecular weight heparin consists of oligosaccharides having a 2-O-sulfo-4-enopyranosuronic acid at one of their ends.
8. (Currently Amended) The method according to one of claims ~~1 to 2~~ or 3, wherein the low molecular weight heparin is obtained by depolymerization of a heparin ester using a base.

9. (Currently Amended) The method according to one of claims ~~1 to 2~~ or 3, wherein the low molecular weight heparin is enoxaparin.
10. (Currently Amended) The method according to one of claims ~~1 to 2~~ or 3, wherein the low molecular weight heparin is nadroparin.
11. (Currently Amended) The method according to one of claims ~~1 to 2~~ or 3, wherein the low molecular weight heparin is parnaparin.
12. (Currently Amended) The method according to one of claims ~~1 to 2~~ or 3, wherein the low molecular weight heparin is reviparin.
13. (Currently Amended) The method according to one of claims ~~1 to 2~~ or 3, wherein the low molecular weight heparin is dalteparin.
14. (Currently Amended) The method according to one of claims ~~1 to 2~~ or 3, wherein the low molecular weight heparin is tinzaparin.
15. (Currently Amended) The method according to one of claims ~~1 to 2~~ or 3, wherein the low molecular weight heparin is danaparoid.
16. (Currently Amended) The method according to one of claims ~~1 to 2~~ or 3, wherein the low molecular weight heparin is ardeparin.
17. (Currently Amended) The method according to one of claims ~~1 to 2~~ or 3, wherein the low molecular weight heparin is certoparin.
18. (Currently Amended) The method according to one of claims ~~1 to 2~~ or 3, wherein the low molecular weight heparin is CY222.
19. (Currently Amended) The method according to one of claims ~~1 to 2~~ or 3, wherein the low molecular weight heparin is SR90107/ORG31540.